The Third Institute for Cancer Vaccines and Immunotherapy (ICVI) symposium on immunotherapy: May 12–13, 2017, Royal Society, London, UK

por Dalgleish, Angus G
Publicado 2018

The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory?

por Galustian, Christine, Dalgleish, Angus G.
Publicado 2010

The failure of radical treatments to cure cancer: can less deliver more?

por Dalgleish, Angus G., Stern, Peter L.
Publicado 2018

The role of immune modulation and anti-inflammatory agents in the management of prostate cancer: A case report of six patients

por Dalgleish, Angus G., Liu, Wai M.
Publicado 2022

Enhanced effect of checkpoint inhibitors when given after or together with IMM-101: significant responses in four advanced melanoma patients with no additional major toxicity

por Dalgleish, Angus G., Mudan, Satvinder, Fusi, Alberto
Publicado 2018

Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors

por Cant, Rachel, Dalgleish, Angus G., Allen, Rachel L.
Publicado 2017

In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells

por Gravett, Andrew M., Dalgleish, Angus G., Copier, John
Publicado 2019

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma

por Dalgleish, Angus G., McLean, Emma, Patel, Nirav, Rahman, Najib
Publicado 2019

Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+) γδ T cell cytotoxicity in a perforin-dependent manner

por Fowler, Daniel W., Copier, John, Dalgleish, Angus G., Bodman-Smith, Mark D.
Publicado 2017

Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and “New Old Friends”

por Kleen, Thomas-Oliver, Galdon, Alicia A., MacDonald, Andrew S., Dalgleish, Angus G.
Publicado 2020

Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

por Fowler, Daniel W., Copier, John, Wilson, Natalie, Dalgleish, Angus G., Bodman-Smith, Mark D.
Publicado 2011

The efficacy of chemotherapeutic drug combinations may be predicted by concordance of gene response to the single agents

por Gravett, Andrew M., Dennis, Jayne L., Dalgleish, Angus G., Copier, John, Liu, Wai M.
Publicado 2020

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer

por Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J., Modjtahedi, Helmout
Publicado 2018

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer

por Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J., Modjtahedi, Helmout
Publicado 2020

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antag...

por Khan, Tanzeel, Seddon, Alan M., Dalgleish, Angus G., Khelwatty, Said, Ioannou, Nikolaos, Mudan, Satvinder, Modjtahedi, Helmout
Publicado 2020

The cytotoxic molecule granulysin is capable of inducing either chemotaxis or fugetaxis in dendritic cells depending on maturation: a role for Vδ2(+) γδ T cells in the modulation o...

por Sparrow, Emma L., Fowler, Daniel W., Fenn, Joe, Caron, Jonathan, Copier, John, Dalgleish, Angus G., Bodman‐Smith, Mark D.
Publicado 2020

Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine()()

por Leeman, Hayley, Kaminska, Elwira, Green, Deborah, Bodman-Smith, Mark, Gravett, Andrew, Bodman-Smith, Katherine, Copier, John, Coulton, Gary, Fusi, Alberto, Dalgleish, Angus G.
Publicado 2018

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

por Dalgleish, Angus G, Stebbing, Justin, Adamson, Douglas JA, Arif, Seema Safia, Bidoli, Paolo, Chang, David, Cheeseman, Sue, Diaz-Beveridge, Robert, Fernandez-Martos, Carlos, Glynne-Jones, Rob, Granetto, Cristina, Massuti, Bartomeu, McAdam, Karen, McDermott, Raymond, Martín, Andrés J Muñoz, Papamichael, Demetris, Pazo-Cid, Roberto, Vieitez, Jose M, Zaniboni, Alberto, Carroll, Kevin J, Wagle, Shama, Gaya, Andrew, Mudan, Satvinder S
Publicado 2016

Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer

por Dalgleish, Angus G, Stebbing, Justin, Adamson, Douglas J A, Arif, Seema Safia, Bidoli, Paolo, Chang, David, Cheeseman, Sue, Diaz-Beveridge, Robert, Fernandez-Martos, Carlos, Glynne-Jones, Rob, Granetto, Cristina, Massuti, Bartomeu, McAdam, Karen, McDermott, Raymond, Martín, Andrés J Muñoz, Papamichael, Demetris, Pazo-Cid, Roberto, Vieitez, Jose M, Zaniboni, Alberto, Carroll, Kevin J, Wagle, Shama, Gaya, Andrew, Mudan, Satvinder S
Publicado 2016

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

por Cebon, Jonathan S, Gore, Martin, Thompson, John F, Davis, Ian D, McArthur, Grant A, Walpole, Euan, Smithers, Mark, Cerundolo, Vincenzo, Dunbar, P Rod, MacGregor, Duncan, Fisher, Cyril, Millward, Michael, Nathan, Paul, Findlay, Michael P N, Hersey, Peter, Evans, T R Jeffry, Ottensmeier, Christian Hermann, Marsden, Jeremy, Dalgleish, Angus G, Corrie, Pippa G, Maria, Marples, Brimble, Margaret, Williams, Geoff, Winkler, Sintia, Jackson, Heather M, Endo-Munoz, Liliana, Tutuka, Candani S A, Venhaus, Ralph, Old, Lloyd J, Haack, Dennis, Maraskovsky, Eugene, Behren, Andreas, Chen, Weisan
Publicado 2020